The presence of a large geriatric and target patient population and the improving healthcare infrastructure in several APAC countries are expected to offer growth opportunities in the market during the forecast period.
The market for osteoarthritis therapeutics is anticipated to be marginally affected due to the outbreak of COVID-19. Among drug types, the use of corticosteroids has reduced. Although there is no evidence to suggest that corticosteroid injections lead to a substantial increase in the risk of infection, there is a possible reduction in the immune response for up to a few weeks following the procedure.
It should also be noted that the WHO, in one of its guidelines for the management of severe acute respiratory infection in patients with coronavirus, suggested avoiding systemic corticosteroids.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=209565994
Topical, oral, and parenteral pain medications are widely used to manage pain associated with osteoarthritis. Although alternatives such as orthopedic braces are used as part of a noninvasive approach for pain management, the adoption of pain medications for the condition is high owing to the ease of administration and the affordability of pain medications.
The adoption of pain medications for the management of pain associated with osteoarthritis is expected to remain high over the coming decade, which is anticipated to propel the growth of the market during the study period.
Remarkable advances have been made in diagnosing, treating, and monitoring disease activity in patients with osteoarthritis, including the conceptualization of personalized OA medications. Essential features of biomarkers that will have clinical relevance for a personalized approach to therapy for RA include the ease of measurement, acceptable levels of sensitivity and specificity, and test methods that are accessible and interpretable by clinicians.
Based on anatomy, the market is segmented into knee, hip, hand, and small-joint osteoarthritis therapeutics. Knee osteoarthritis therapeutics is the largest and the fastest-growing segment in this market. This can primarily be attributed to the high incidence of knee osteoarthritis.
The new market study by Precise Market Intelligence (PMI) provides in-depth analysis and projects the trajectory of the global Osteoarthritis Therapeutics market between 2020 and 2027.
The research report postulates several macro-economic factors ranging from government decisions, changing consumer preferences, etc.
to significant trends that are likely to influence the growth of the global Osteoarthritis Therapeutics market in the forthcoming years.
This report maps the impact of each market dynamic, such as drivers, trends, and restraints, on every segment and the involved stakeholders of the Osteoarthritis Therapeutics market.
The understanding of the impact on each segment bolsters stakeholders – including manufacturers, suppliers, and retailers – to develop strategies to leverage the forthcoming changes in the Osteoarthritis Therapeutics landscape.PMI’s analysts have compiled a comprehensive report using modern-day research methods that paints a transparent picture of the direction the market is headed in and will aid players in making the right decisions.For More Insights Into The Market, Request a Sample of This Report@ https://www.precisemarketintelligence.com/sample/12 Impact of COVID-19 on Osteoarthritis Therapeutics MarketThe unforeseen outbreak of COVID-19 has brought the global Healthcare sector to a screeching halt, and the Osteoarthritis Therapeutics market is no exception.
Perils of the pandemic such as halted productions disrupted supply chains, and depreciation in demand for Healthcare have led to a downtrend in the growth trajectory of the Osteoarthritis Therapeutics market.
